BCR/ABL1 qRT PCR
Use
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for the detection of the major BCR::ABL fusion gene transcript p210 (e13/e14a2) in patients with a Philadelphia (t[(9;22)(q34;q11.2)]) positive leukemia. The BCR::ABL major translocation is found in >99% of CML patients. Results for the major BCR::ABL fusion gene transcripts are reported on the international scale (IS).
Special Instructions
Not provided.
Limitations
Specimen must be received by MPLN within 48 hours of collection. The test is not FDA approved and is for research use only (RUO). The performance of this test in the context of minimal residual disease (MRD) testing can be affected by certain parameters, such as sample preparation and RNA quality.
Methodology
PCR-based (qPCR)
Biomarkers
BCR-ABL1 fusion
Fusion
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
5 mL
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2-8°C
Causes for Rejection
Specimen >48 hours old; Specimen clotted; Specimen stored or shipped at incorrect temperature; Specimen in incorrect anticoagulant; Insufficient specimen volume; Isolated RNA of suboptimal quantity and/or quality
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 48 hours |